Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Gut

• Publication date

  2004-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gut.2003.037747PMID 15479682PMCID PMC1774300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral administration of a certain strain of liveEscherichia coli for intestinal disorders?

  2005cited by this paper
• [Chronic constipation].

  2004cited by this paper
• Maintenance treatment of Crohn's disease

  2003cited by this paper
• Use of Probiotics in the Treatment of Inflammatory Bowel Disease

  2003cited by this paper
• A Single Nucleotide Exchange in the wzy Gene Is Responsible for the Semirough O6 Lipopolysaccharide Phenotype and Serum Sensitivity of Escherichia coli Strain Nissle 1917

  2002cited by this paper
• Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E. coli Strain Nissle 1917

  2002cited by this paper
• Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG

  2002cited by this paper
• Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic E. coli strain Nissle 1917

  2001cited by this paper
• [Diagnosis and therapy of ulcerative colitis--results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases].

  2001cited by this paper
• Diagnostik und Therapie der Colitis ulcerosa - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten1

  2001cited by this paper
• Bacteria as the cause of ulcerative colitis

  2001cited by this paper
• Escherichia coli strain nissie 1917 inhibits adhesion to an invasion of intestinal epithelial cells by adherent-invasive E. colil isolated from a Crohn's disease patient

  2001cited by this paper
• Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis

  2001cited by this paper
• Prokaryotic Regulation of Epithelial Responses by Inhibition of IκB-α Ubiquitination

  2000cited by this paper
• Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

  2000cited by this paper
• Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial

  2000cited by this paper
• Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease

  2000cited by this paper
• Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

  2000cited by this paper
• REVIEW: Antibacterial Therapy for Crohn's Disease: A Review Emphasizing Therapy Directed Against Mycobacteria

  2000cited by this paper
• Probiotics and inflammatory bowel disease: is there a scientific rationale?

  2000cited by this paper
• [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].

  2000cited by this paper
• Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.

  2000cited by this paper
• Therapy with E.coli nissle reduces concentrations of mucosa associated colonic flora in patients with ulcerative colitis

  2000cited by this paper
• Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis

  1999cited by this paper
• Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

  1999cited by this paper
• What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

  1998cited by this paper
• Postoperative recurrence of Crohn's disease: the enemy is within the fecal stream.

  1998cited by this paper
• Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.

  1998cited by this paper
• Alternatives to Sulfasalazine: A Meta‐analysis of 5‐ASA in the Treatment of Ulcerative Colitis

  1997cited by this paper
• Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

  1997cited by this paper
• Enteric Microflora in IBD: Pathogens or Commensals?

  1997cited by this paper
• Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

  1997cited by this paper
• Properties ofEscherichia coli strains of serotype O6

  1995cited by this paper
• Re.: Oral administration of a certain strain of liveEscherichia coli for intestinal disorders? (Infection 23 [1995] 51–54)

  1995cited by this paper
• Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.

  1995cited by this paper
• Salicylates for ulcerative colitis--their mode of action.

  1994cited by this paper
• [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)].

  1994cited by this paper
• Microscopic activity in ulcerative colitis: what does it mean?

  1991cited by this paper
• Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk.

  1990cited by this paper
• Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

  1989cited by this paper
• A new measure of health status for clinical trials in inflammatory bowel disease.

  1989cited by this paper

• Probiotic therapeutics: A critical review of mechanisms, clinical efficacy, and the frontier of precision microbiome modulation.

  2026cites this paper
• Human Microbiota-Associated Pig Models for Translational Microbiome Research: A Scoping Review.

  2026cites this paper
• Lactobacillus plantarum AR113 alleviates Western Diet-Induced colitis and liver injury via bidirectional modulation of the Intestinal-Hepatic FXR signaling axis.

  2026cites this paper
• Overview of the immunomodulatory role of bacterial probiotic-derived peptidoglycan: from molecular insights to therapeutic application

  2026cites this paper
• Subacute 28-Day OECD-Guided Oral Toxicity Study of Escherichia coli 5C (LMG S-33222) in Wistar Rats and Immunocompromised Nude Mice

  2026cites this paper
• Preclinical Evaluation of Synthetic Biology-Driven Engineered Escherichia coli Nissle 1917 as a Living Therapeutic for Sustained L-DOPA Delivery.

  2026cites this paper
• Gut microbiome in IBD: past, present and the future

  2025cites this paper
• Beyond the “Master” Role in Allergy: Insights into Intestinal Mast Cell Plasticity and Gastrointestinal Diseases

  2025cites this paper
• Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects.

  2025cites this paper
• Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence

  2025cites this paper
• Intestinal amino acid metabolic response and its roles in inflammatory bowel disease

  2025cites this paper
• Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration

  2025cites this paper
• An Integrated Engineering Approach to Creating Health‐Modulating Postbiotics

  2025cites this paper
• A Non-genotoxic Variant of Escherichia coli Nissle 1917 EcN 2.0 Overexpressing Microcins Reduces Intestinal Carriage of ST131 ESBL-Producing Escherichia coli.

  2025cites this paper
• Oral pretreatment with Escherichia coli Nissle 1917 enhances the host's defense against influenza A virus infection

  2025cites this paper
• Research status and development trends of probiotics in clinical applications

  2025cites this paper
• Generating theranostic bacteria by depositing a protective visual therapeutic nanocoating via in situ sequential mineralization

  2025cites this paper
• Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential

  2025cites this paper
• Genetically-programmed Hypervesiculation of Lactiplantibacillus plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model

  2025cites this paper
• Expressing Vitreoscilla hemoglobin in Escherichia coli Nissle 1917 enhances its probiotic potential for alleviating ulcerative colitis.

  2025cites this paper
• Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities

  2025cites this paper
• Neutrophil recruitment during intestinal inflammation primes Salmonella elimination by commensal E. coli in a context-dependent manner.

  2025cites this paper
• Challenges and Opportunities in Analyzing Cancer-Associated Microbiomes.

  2025cites this paper
• Fabrication of Single-Bacterium Microgel with Gas-Shearing Strategy for Precision Probiotic Delivery in IBD Therapy

  2025cites this paper
• Commensal human gut microbes produce species specific neuroactive compounds

  2025cites this paper
• Biomarkers of Probiotic Therapy in Ulcerative Colitis: A Systematic Review of Mechanisms Underlying Remission

  2025influential citation
• Selection, Comparative Genomics, and Potential Probiotic Features of Escherichia coli 5C, a pks-Negative Strain Isolated from Healthy Infant Donor Feces.

  2025cites this paper
• Natural and Biological Products Therapeutic Potential in Restoring Gut Microbiome: Mechanistic Insights and Clinical Implications.

  2025cites this paper
• Akkermansia muciniphila Protects Against Trinitrobenzene Sulfonic Acid Induced Colitis by Inhibiting IL6/STAT3 Pathway.

  2025cites this paper
• Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease

  2025cites this paper
• Therapeutic Potential of Short-Chain Fatty Acids in Gastrointestinal Diseases

  2025cites this paper
• Commensal Escherichia coli colonization triggers Peyer’s patch development

  2025cites this paper
• Next-generation probiotics and engineered BEVs for precision therapeutics in osteoporosis

  2025cites this paper
• In vivo systematic analysis of microbiota-prebiotic crosstalk reveals a synbiotic that effectively ameliorates DSS-induced colitis in mice

  2025cites this paper
• An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis

  2025cites this paper
• The role of dietary factors in the prevention and management of inflammatory bowel disease: a comprehensive review

  2025cites this paper
• Composition and Interactions of the Oral–Gastrointestinal Microbiome Populations During Health, Disease, and Long-Duration Space Missions: A Narrative Review

  2025cites this paper
• Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management

  2025cites this paper
• Phylogroup Homeostasis of Escherichia coli in the Human Gut Reflects the Physiological State of the Host

  2025cites this paper
• The effects of candidate probiotic strains on the gut environment in dextran sulfate sodium-induced colitis mouse

  2025cites this paper
• Gut Microbiota in IBD: The Beneficial and Adverse Effects of Diet and Medication

  2025cites this paper
• Gut microbiota — bidirectional modulator: role in inflammatory bowel disease and colorectal cancer

  2025cites this paper
• Amebicidal Activity of Escherichia coli Nissle 1917 Against Entamoeba histolytica

  2025cites this paper
• Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial

  2025cites this paper
• Diet in Inflammatory Bowel Diseases: Efficacy, Tolerability, and Microbiome Effects Toward Personalized Management.

  2025cites this paper
• Genetically‐Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model

  2025cites this paper
• Different probiotic formulations in ulcerative colitis: A bayesian network meta-analysis

  2024cites this paper
• Bifidobacterium longum subsp. longum relieves loperamide hydrochloride-induced constipation in mice by enhancing bile acid dissociation.

  2024cites this paper
• Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease

  2024cites this paper
• The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases

  2024cites this paper
• Nutrition of Escherichia coli within the intestinal microbiome

  2024cites this paper
• Gut Microbiome as a Target of Intervention in Inflammatory Bowel Disease Pathogenesis and Therapy

  2024cites this paper
• Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease.

  2024cites this paper
• The Role of Gut Microbiota, Immune System, and Autophagy in the Pathogenesis of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutic Approaches

  2024cites this paper
• Metabolic-methane mitigation by combination of probiotic Escherichia coli strain Nissle 1917 and biochar in rumen fluid in vitro fermentation of dairy cow

  2024cites this paper
• A living organoid biobank of patients with Crohn’s disease reveals molecular subtypes for personalized therapeutics

  2024cites this paper
• Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents

  2024cites this paper
• The Urinary Microbiome Is a Potential Driver of Urinary Tract Pathology Through Multiple Mechanisms Including Deglucuronidation and DNA Damage.

  2024cites this paper
• Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus-Based Nutraceutical Add-on Multi-Compound: The “HERICIUM-UC” Two-Arm Multicentre Retrospective Study

  2024cites this paper
• From probiotic chassis to modification strategies, control and improvement of genetically engineered probiotics for inflammatory bowel disease.

  2024cites this paper
• Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials

  2024cites this paper
• Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis

  2024cites this paper
• Escherichia coli Nissle 1917 Protects against Sepsis-Induced Intestinal Damage by Regulating the SCFA/GPRs Signaling Pathway

  2024cites this paper
• A Comprehensive Analysis of Efficacy and Safety of Probiotics in Inflammatory Bowel Disease

  2024cites this paper
• Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease

  2024influential citation
• Hyperbaric oxygen enhances tumor penetration and accumulation of engineered bacteria for synergistic photothermal immunotherapy

  2024cites this paper
• Nano-armor modification of bacteria through supramolecular interactions for disease treatment

  2024cites this paper
• The biogeography of the mucosa-associated microbiome in health and disease

  2024cites this paper
• Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

  2024cites this paper
• Probiotics for inflammatory bowel disease: Is there sufficient evidence?

  2024cites this paper
• Bidirectional communication of the gut-brain axis: new findings in Parkinson’s disease and inflammatory bowel disease

  2024cites this paper
• Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials

  2024cites this paper
• MnO2 and roflumilast-loaded probiotic membrane vesicles mitigate experimental colitis by synergistically augmenting cAMP in macrophage

  2024cites this paper
• Constituents of stable commensal microbiota imply diverse colonic epithelial cell reactivity in patients with ulcerative colitis

  2024cites this paper
• The value of increased intestinal permeability in the pathogenesis of internal diseases

  2024cites this paper
• Recombinant probiotic Lactococcus lactis delivering P62 mitigates moderate colitis in mice

  2024cites this paper
• What We Know About the Actual Role of Traditional Probiotics in Health and Disease

  2024cites this paper
• Dual engineered bacteria improve inflammatory bowel disease in mice

  2024cites this paper
• Biotic resistance predictably shifts microbial invasion regimes

  2024cites this paper
• Genetic Circuits for Feedback Control of Gamma-Aminobutyric Acid Biosynthesis in Probiotic Escherichia coli Nissle 1917

  2024cites this paper
• World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics.

  2024cites this paper
• Engineering a Novel Probiotic Toolkit in Escherichia coliNissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases

  2024cites this paper
• The role of the fecal microbiota in inflammatory bowel disease

  2024cites this paper
• Diminished Immune Response and Elevated Abundance in Gut Microbe Dubosiella in Mouse Models of Chronic Colitis with GBP5 Deficiency

  2024cites this paper
• Clickable nanozyme enhances precise colonization of probiotics for ameliorating inflammatory bowel disease.

  2024cites this paper
• Unraveling Interactions Between Gut Epithelium and Microbiota Using Models of Intestinal Organoids

  2024cites this paper
• Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment

  2024cites this paper
• Next generation probiotics: Engineering live biotherapeutics.

  2024cites this paper
• Probiotic use in pediatric kidney transplant recipients: What are current practices, and are they evidence‐based? A pediatric nephrology research consortium study

  2024cites this paper
• Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

  2023cites this paper
• Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey

  2023cites this paper
• Therapeutic Effects of Zymomonas mobilis on Experimental DSS-Induced Colitis Mouse Model

  2023cites this paper
• Does Neonatal Microbiome Research Encompass the Placental Transfer Pathway?

  2023cites this paper
• Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease

  2023cites this paper
• Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease—An Overview

  2023cites this paper
• Crosstalk between gut microbiota and gut resident macrophages in inflammatory bowel disease

  2023cites this paper
• Delivery of E. coli Nissle to the mouse gut by mucoadhesive microcontainers does not improve its competitive ability against strains linked to ulcerative colitis

  2023cites this paper
• Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease

  2023cites this paper
• Engineered live bacteria as disease detection and diagnosis tools

  2023cites this paper
• Effects of Probiotics in Adults with Gastroenteritis: A Systematic Review and Meta-Analysis of Clinical Trials

  2023cites this paper